ANTI IL-33 THERAPEUTIC AGENT FPR TREATING RENAL DISORDERS

The present disclosure relates to a method of treating kidney injury, by administering an anti-IL- 33 therapeutic agent which inhibits both ST2 signaling and RAGE signaling. La présente invention concerne un procédé de traitement d'une lésion rénale, par administration d'un agent thérapeut...

Full description

Saved in:
Bibliographic Details
Main Authors WOOLLARD, KEVIN JAMES, STRICKSON, SAM, BAKER, DAVID JAMES, SETH, ASHA, LIARTE MARIN, ELENA, COHEN, EMMA SUZANNE, MORENO QUINN, CAROL PATRICIA, MUSIAL, BARBARA, HOUSLAY, KIRSTY
Format Patent
LanguageEnglish
French
Published 14.05.2021
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present disclosure relates to a method of treating kidney injury, by administering an anti-IL- 33 therapeutic agent which inhibits both ST2 signaling and RAGE signaling. La présente invention concerne un procédé de traitement d'une lésion rénale, par administration d'un agent thérapeutique anti-IL-33 qui inhibe à la fois la signalisation ST2 et la signalisation RAGE.
Bibliography:Application Number: CA20203158366